Cholestatic phenotypes of autoimmune hepatitis

Clinical Gastroenterology and Hepatology

Volumn 12, Issue 9, 2014, Pages 1430-1438

  Czaja, Albert J ^a  

^a MAYO CLINIC   (United States)

Author keywords

Atypical phenotypes; Autoimmune hepatitis; Cholestasis; Overlap

Indexed keywords

ALKALINE PHOSPHATASE; CORTICOSTEROID; GAMMA GLUTAMYLTRANSFERASE; MITOCHONDRION ANTIBODY; URSODEOXYCHOLIC ACID;

ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASCITES; AUTOIMMUNE HEPATITIS; AUTOIMMUNE LIVER DISEASE; BILE DUCT INJURY; CHOLANGIOGRAPHY; CHOLESTASIS; CORTICOSTEROID THERAPY; ENZYME IMMUNOASSAY; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GASTROINTESTINAL HEMORRHAGE; HISTOPATHOLOGY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER CIRRHOSIS; OUTCOME ASSESSMENT; PHENOTYPE; PORTAL HYPERTENSION; PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; REMISSION; SCORING SYSTEM; ULCERATIVE COLITIS; UNCERTAINTY; CHOLANGITIS; DISEASE CLASSIFICATION; DISEASE COURSE; PATHOGENESIS; SEROLOGY; TREATMENT OUTCOME; BILE DUCT; BLOOD; COMPLICATION; CYTOCHEMISTRY; DIFFERENTIAL DIAGNOSIS; HEPATITIS, AUTOIMMUNE; PATHOLOGY;

ALKALINE PHOSPHATASE; BILE DUCTS; CHOLANGIOGRAPHY; CHOLESTASIS; DIAGNOSIS, DIFFERENTIAL; GAMMA-GLUTAMYLTRANSFERASE; HEPATITIS, AUTOIMMUNE; HISTOCYTOCHEMISTRY; HUMANS; TREATMENT OUTCOME;

EID: 84906789807     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2013.08.039     Document Type: Article

References (81)

1. Manns M.P., Czaja A.J., Gorham J.D., et al. Practice Guidelines of the American Association for the Study of Liver Diseases. Diagnosis and management of autoimmune hepatitis. Hepatology 2010, 51:2193-2213.
2. Alvarez F., Berg P.A., Bianchi F.B., et al. International Autoimmune Hepatitis Group report: review of criteria for diagnosis of autoimmune hepatitis. JHepatol 1999, 31:929-938.
3. Czaja A.J. The variant forms of autoimmune hepatitis. Ann Intern Med 1996, 125:588-598.
4. Czaja A.J. Frequency and nature of the variant syndromes of autoimmune liver disease. Hepatology 1998, 28:360-365.
5. Ben-Ari Z., Czaja A.J. Autoimmune hepatitis and its variant syndromes. Gut 2001, 49:589-594.
6. Lindor K.D., Gershwin M.E., Poupon R., et al. AASLD Practice Guidelines. Primary biliary cirrhosis. Hepatology 2009, 50:291-308.
7. Chapman R., Fevery J., Kalloo A., et al. Diagnosis and management of primary sclerosing cholangitis. Hepatology 2010, 51:660-678.
8. Boberg K.M., Chapman R.W., Hirschfield G.M., et al. Overlap syndromes: the International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue. JHepatol 2011, 54:374-385.
9. Czaja A.J. The overlap syndromes of autoimmune hepatitis. Dig Dis Sci 2013, 58:326-343.
10. Czaja A.J. Diagnosis and management of the overlap syndromes of autoimmune hepatitis. Can J Gastroenterol 2013, 27:417-423.
11. Christoffersen P., Dietrichson O., Faber V., et al. The occurrence and significance of abnormal bile duct epithelium in chronic aggressive hepatitis. A comparative morphological biochemical, immunological, and prognostic study. Acta Pathol Microbiol Scand 1972, 80:294-302.
12. Kloppel G., Seifert G., Lindner H., et al. Histopathological features in mixed types of chronic aggressive hepatitis and primary biliary cirrhosis. Correlations of liver histology with mitochondrial antibodies of different specificity. Virchows Arch A Pathol Anat Histol 1977, 373:143-160.
13. Geubel A.P., Baggenstoss A.H., Summerskill W.H. Responses to treatment can differentiate chronic active liver disease with cholangitic features from the primary biliary cirrhosis syndrome. Gastroenterology 1976, 71:444-449.
14. Kenny R.P., Czaja A.J., Ludwig J., et al. Frequency and significance of antimitochondrial antibodies in severe chronic active hepatitis. Dig Dis Sci 1986, 31:705-711.
15. Perdigoto R., Carpenter H.A., Czaja A.J. Frequency and significance of chronic ulcerative colitis in severe corticosteroid-treated autoimmune hepatitis. JHepatol 1992, 14:325-331.
16. Kim W.R., Ludwig J., Lindor K.D. Variant forms of cholestatic diseases involving small bile ducts in adults. Am J Gastroenterol 2000, 95:1130-1138.
17. Olsson R., Glaumann H., Almer S., et al. High prevalence of small duct primary sclerosing cholangitis among patients with overlapping autoimmune hepatitis and primary sclerosing cholangitis. Eur J Intern Med 2009, 20:190-196.
18. Silveira M.G., Talwalkar J.A., Angulo P., et al. Overlap of autoimmune hepatitis and primary biliary cirrhosis: long-term outcomes. Am J Gastroenterol 2007, 102:1244-1250.
19. Al-Chalabi T., Portmann B.C., Bernal W., et al. Autoimmune hepatitis overlap syndromes: an evaluation of treatment response, long-term outcome and survival. Aliment Pharmacol Ther 2008, 28:209-220.
20. Muratori P., Granito A., Quarneti C., et al. Autoimmune hepatitis in Italy: the Bologna experience. JHepatol 2009, 50:1210-1218.
21. Zachou K., Gatselis N., Papadamou G., et al. Mycophenolate for the treatment of autoimmune hepatitis: prospective assessment of its efficacy and safety for induction and maintenance of remission in a large cohort of treatment-naive patients. JHepatol 2011, 55:636-646.
22. Ludwig J., Czaja A.J., Dickson E.R., et al. Manifestations of nonsuppurative cholangitis in chronic hepatobiliary diseases: morphologic spectrum, clinical correlations and terminology. Liver 1984, 4:105-116.
23. Czaja A.J., Carpenter H.A. Sensitivity, specificity, and predictability of biopsy interpretations in chronic hepatitis. Gastroenterology 1993, 105:1824-1832.
24. Czaja A.J., Carpenter H.A., Santrach P.J., et al. Autoimmune cholangitis within the spectrum of autoimmune liver disease. Hepatology 2000, 31:1231-1238.
25. Czaja A.J., Muratori P., Muratori L., et al. Diagnostic and therapeutic implications of bile duct injury in autoimmune hepatitis. Liver Int 2004, 24:322-329.
26. Lewin M., Vilgrain V., Ozenne V., et al. Prevalence of sclerosing cholangitis in adults with autoimmune hepatitis: a prospective magnetic resonance imaging and histological study. Hepatology 2009, 50:528-537.
27. Abdalian R., Dhar P., Jhaveri K., et al. Prevalence of sclerosing cholangitis in adults with autoimmune hepatitis: evaluating the role of routine magnetic resonance imaging. Hepatology 2008, 47:949-957.
28. Gregorio G.V., Portmann B., Karani J., et al. Autoimmune hepatitis/sclerosing cholangitis overlap syndrome in childhood: a 16-year prospective study. Hepatology 2001, 33:544-553.
29. Czaja A.J., Carpenter H.A., Manns M.P. Antibodies to soluble liver antigen, P450IID6, and mitochondrial complexes in chronic hepatitis. Gastroenterology 1993, 105:1522-1528.
30. Montano-Loza A.J., Carpenter H.A., Czaja A.J. Frequency, behavior, and prognostic implications of antimitochondrial antibodies in type 1 autoimmune hepatitis. JClin Gastroenterol 2008, 42:1047-1053.
31. Nezu S., Tanaka A., Yasui H., et al. Presence of antimitochondrial autoantibodies in patients with autoimmune hepatitis. JGastroenterol Hepatol 2006, 21:1448-1454.
32. Hennes E.M., Zeniya M., Czaja A.J., et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology 2008, 48:169-176.
33. Papamichalis P.A., Zachou K., Koukoulis G.K., et al. The revised international autoimmune hepatitis score in chronic liver diseases including autoimmune hepatitis/overlap syndromes and autoimmune hepatitis with concurrent other liver disorders. JAutoimmune Dis 2007, 4:3.
34. Gatselis N.K., Zachou K., Papamichalis P., et al. Comparison of simplified score with the revised original score for the diagnosis of autoimmune hepatitis: a new or a complementary diagnostic score?. Dig Liver Dis 2010, 42:807-812.
35. Milkiewicz P., Buwaneswaran H., Coltescu C., et al. Value of autoantibody analysis in the differential diagnosis of chronic cholestatic liver disease. Clin Gastroenterol Hepatol 2009, 7:1355-1360.
36. Muratori P., Granito A., Pappas G., et al. The serological profile of the autoimmune hepatitis/primary biliary cirrhosis overlap syndrome. Am J Gastroenterol 2009, 104:1420-1425.
37. Beuers U., Boberg K.M., Chapman R.W., et al. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. JHepatol 2009, 51:237-267.
38. Chazouilleres O., Wendum D., Serfaty L., et al. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy. Hepatology 1998, 28:296-301.
39. Kuiper E.M., Zondervan P.E., van Buuren H.R. Paris criteria are effective in diagnosis of primary biliary cirrhosis and autoimmune hepatitis overlap syndrome. Clin Gastroenterol Hepatol 2010, 8:530-534.
40. Bonder A., Retana A., Winston D.M., et al. Prevalence of primary biliary cirrhosis-autoimmune hepatitis overlap syndrome. Clin Gastroenterol Hepatol 2011, 9:609-612.
41. McNair A.N., Moloney M., Portmann B.C., et al. Autoimmune hepatitis overlapping with primary sclerosing cholangitis in five cases. Am J Gastroenterol 1998, 93:777-784.
42. Gohlke F., Lohse A.W., Dienes H.P., et al. Evidence for an overlap syndrome of autoimmune hepatitis and primary sclerosing cholangitis. JHepatol 1996, 24:699-705.
43. Carpenter H.A., Czaja A.J. The role of histologic evaluation in the diagnosis and management of autoimmune hepatitis and its variants. Clin Liver Dis 2002, 6:685-705.
44. Trivedi P.J., Chapman R.W. PSC, AIH and overlap syndrome in inflammatory bowel disease. Clin Res Hepatol Gastroenterol 2012, 36:420-436.
45. Lindstrom L., Hultcrantz R., Boberg K.M., et al. Association between reduced levels of alkaline phosphatase and survival times of patients with primary sclerosing cholangitis. Clin Gastroenterol Hepatol 2013, 11:841-846.
46. Taylor S.L., Dean P.J., Riely C.A. Primary autoimmune cholangitis. An alternative to antimitochondrial antibody-negative primary biliary cirrhosis. Am J Surg Pathol 1994, 18:91-99.
47. Michieletti P., Wanless I.R., Katz A., et al. Antimitochondrial antibody negative primary biliary cirrhosis: a distinct syndrome of autoimmune cholangitis. Gut 1994, 35:260-265.
48. Invernizzi P., Crosignani A., Battezzati P.M., et al. Comparison of the clinical features and clinical course of antimitochondrial antibody-positive and -negative primary biliary cirrhosis. Hepatology 1997, 25:1090-1095.
49. Muratori P., Muratori L., Gershwin M.E., et al. 'True' antimitochondrial antibody-negative primary biliary cirrhosis, low sensitivity of the routine assays, or both?. Clin Exp Immunol 2004, 135:154-158.
50. Angulo P., Maor-Kendler Y., Lindor K.D. Small-duct primary sclerosing cholangitis: a long-term follow-up study. Hepatology 2002, 35:1494-1500.
51. Heurgue A., Vitry F., Diebold M.D., et al. Overlap syndrome of primary biliary cirrhosis and autoimmune hepatitis: a retrospective study of 115 cases of autoimmune liver disease. Gastroenterol Clin Biol 2007, 31:17-25.
52. Gheorghe L., Iacob S., Gheorghe C., et al. Frequency and predictive factors for overlap syndrome between autoimmune hepatitis and primary cholestatic liver disease. Eur J Gastroenterol Hepatol 2004, 16:585-592.
53. Muratori L., Cassani F., Pappas G., et al. The hepatitic/cholestatic "overlap" syndrome: an Italian experience. Autoimmunity 2002, 35:565-568.
54. Hunter M., Loughrey M.B., Gray M., et al. Evaluating distinctive features for early diagnosis of primary sclerosing cholangitis overlap syndrome in adults with autoimmune hepatitis. Ulster Med J 2011, 80:15-18.
55. Kayacetin E., Koklu S., Temucin T. Overlap syndrome of primary biliary cirrhosis and autoimmune hepatitis with unusual initial presentation as fulminant hepatic failure. Dig Liver Dis 2004, 36:419-422.
56. Koskinas J., Raptis I., Manika Z., et al. Overlapping syndrome of autoimmune hepatitis and primary sclerosing cholangitis associated with pyoderma gangrenosum and ulcerative colitis. Eur J Gastroenterol Hepatol 1999, 11:1421-1424.
57. Arulprakash S., Sasi A.D., Bala M.R., et al. Overlap syndrome: autoimmune hepatitis with primary biliary cirrhosis. JAssoc Physicians India 2010, 58:455-456.
58. Lee W.S., Saw C.B., Sarji S.A. Autoimmune hepatitis/primary sclerosing cholangitis overlap syndrome in a child: diagnostic usefulness of magnetic resonance cholangiopancreatography. JPaediatr Child Health 2005, 41:225-227.
59. Takiguchi J., Ohira H., Rai T., et al. Autoimmune hepatitis overlapping with primary sclerosing cholangitis. Intern Med 2002, 41:696-700.
60. Czaja A.J. Overlap syndrome of primary biliary cirrhosis and autoimmune hepatitis: a foray across diagnostic boundaries. JHepatol 2006, 44:251-252.
61. Durazzo M., Premoli A., Paschetta E., et al. Overlap syndromes of autoimmune hepatitis: an open question. Dig Dis Sci 2013, 58:344-348.
62. Lohse A.W., zum Buschenfelde K.H., Franz B., et al. Characterization of the overlap syndrome of primary biliary cirrhosis (PBC) and autoimmune hepatitis: evidence for it being a hepatitic form of PBC in genetically susceptible individuals. Hepatology 1999, 29:1078-1084.
63. Burak K.W., Urbanski S.J., Swain M.G. Acase of coexisting primary biliary cirrhosis and primary sclerosing cholangitis: a new overlap of autoimmune liver diseases. Dig Dis Sci 2001, 46:2043-2047.
64. Jeevagan A. Overlap of primary biliary cirrhosis and primary sclerosing cholangitis-a rare coincidence or a new syndrome. Int J Gen Med 2010, 3:143-146.
65. Abdo A.A., Bain V.G., Kichian K., et al. Evolution of autoimmune hepatitis to primary sclerosing cholangitis: a sequential syndrome. Hepatology 2002, 36:1393-1399.
66. Poupon R., Chazouilleres O., Corpechot C., et al. Development of autoimmune hepatitis in patients with typical primary biliary cirrhosis. Hepatology 2006, 44:85-90.
67. Lindgren S., Glaumann H., Almer S., et al. Transitions between variant forms of primary biliary cirrhosis during long-term follow-up. Eur J Intern Med 2009, 20:398-402.
68. Czaja A.J., Carpenter H.A. Autoimmune hepatitis with incidental histologic features of bile duct injury. Hepatology 2001, 34:659-665.
69. Domschke W., Klein R., Terracciano L.M., et al. Sequential occurrence of primary sclerosing cholangitis and autoimmune hepatitis type III in a patient with ulcerative colitis: a follow up study over 14 years. Liver 2000, 20:340-345.
70. Poupon R. Autoimmune overlapping syndromes. Clin Liver Dis 2003, 7:865-878.
71. Czaja A.J., Santrach P.J., Breanndan Moore S. Shared genetic risk factors in autoimmune liver disease. Dig Dis Sci 2001, 46:140-147.
72. Doherty D.G., Penzotti J.E., Koelle D.M., et al. Structural basis of specificity and degeneracy of T cell recognition: pluriallelic restriction of T cell responses to a peptide antigen involves both specific and promiscuous interactions between the T cell receptor, peptide, and HLA-DR. JImmunol 1998, 161:3527-3535.
73. Czaja A.J. Genetic factors affecting the occurrence, clinical phenotype, and outcome of autoimmune hepatitis. Clin Gastroenterol Hepatol 2008, 6:379-388.
74. Stanich P.P., Bjornsson E., Gossard A.A., et al. Alkaline phosphatase normalization is associated with better prognosis in primary sclerosing cholangitis. Dig Liver Dis 2011, 43:309-313.
75. Chazouilleres O., Wendum D., Serfaty L., et al. Long term outcome and response to therapy of primary biliary cirrhosis-autoimmune hepatitis overlap syndrome. JHepatol 2006, 44:400-406.
76. Joshi S., Cauch-Dudek K., Wanless I.R., et al. Primary biliary cirrhosis with addtional features of autoimmune hepatitis: response to therapy with ursodeoxycholic acid. Hepatology 2002, 35:409-413.
77. Efe C, Ozaslan E, Kav T, et al. Liver fibrosis may reduce the efficacy of budesonide in the treatment of autoimmune hepatitis and overlap syndrome. Autoimmun Rev 2012, 11:330-334.
78. Talwalkar J.A., Angulo P., Keach J.C., et al. Mycophenolate mofetil for the treatment of primary sclerosing cholangitis. Am J Gastroenterol 2005, 100:308-312.
79. Aw M.M., Dhawan A., Samyn M., et al. Mycophenolate mofetil asrescue treatment for autoimmune liver disease in children: a5-year follow-up. JHepatol 2009, 51:156-160.
80. Floreani A., Rizzotto E.R., Ferrara F., et al. Clinical course and outcome of autoimmune hepatitis/primary sclerosing cholangitis overlap syndrome. Am J Gastroenterol 2005, 100:1516-1522.
81. Sinakos E., Marschall H.U., Kowdley K.V., et al. Bile acid changes after high-dose ursodeoxycholic acid treatment in primary sclerosing cholangitis: relation to disease progression. Hepatology 2010, 52:197-203.